Rivastigmine for Dementia Associated with Parkinson's Disease

In this 24-week randomized study of patients with dementia associated with Parkinson's disease, outcomes were better among patients treated with rivastigmine than among those who received placebo. Clinicians observed clinical improvement in 19.8 percent of patients in the rivastigmine group and...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2004-12, Vol.351 (24), p.2509-2518
Hauptverfasser:	Emre, Murat, Aarsland, Dag, Albanese, Alberto, Byrne, E. Jane, Deuschl, Günther, De Deyn, Peter P, Durif, Franck, Kulisevsky, Jaime, van Laar, Teus, Lees, Andrew, Poewe, Werner, Robillard, Alain, Rosa, Mario M, Wolters, Erik, Quarg, Peter, Tekin, Sibel, Lane, Roger
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Biological and medical sciences Cholinesterase Inhibitors - adverse effects Cholinesterase Inhibitors - therapeutic use Clinical outcomes Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases Dementia Dementia - drug therapy Dementia - etiology Double-Blind Method Female General aspects Humans Male Medical diagnosis Medical sciences Middle Aged Nausea - chemically induced Neurology Parkinson Disease - complications Parkinson's disease Phenylcarbamates - adverse effects Phenylcarbamates - therapeutic use Placebo effect Rivastigmine Tremor - chemically induced Vomiting - chemically induced
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!